TRT health risks: separating real data from gym-bro mythology

What did @chriswillx actually say?

The core argument here is a risk-framing one: if you're clinically deficient in testosterone, the question isn't just "what are the risks of TRT" but also "what are the risks of leaving low testosterone untreated." He frames TRT as potentially protective against cardiovascular disease and neurodegeneration in genuinely deficient men, and cautions that getting on it without actually needing it could make you "less healthy." That's a more nuanced position than most TikTok TRT content, and it's worth unpacking carefully.

He stops short of specific medical claims, repeatedly flagging this is "not medical advice," and frames everything as general population-level reasoning. The argument is essentially: for clinically hypogonadal men, the calculus around TRT risks looks different than for men with normal testosterone who are using it for optimization.

Does the science back this up?

Largely, yes, though the evidence is more complicated than the framing suggests. The claim that untreated hypogonadism raises cardiovascular and cognitive risk has real support, but the idea that TRT cleanly "staves off" those outcomes is still being worked out in trials.

The landmark TRAVERSE trial (Lincoff et al., 2023, New England Journal of Medicine) followed over 5,000 middle-aged and older men with hypogonadism and found testosterone replacement did not significantly increase major cardiovascular events compared to placebo. That's reassuring for safety, but it doesn't prove TRT actively prevents cardiovascular disease. On the neurodegeneration side, observational data, including work by Muraleedharan et al. (2013, European Journal of Endocrinology), found low testosterone in men with type 2 diabetes was associated with higher all-cause mortality and cognitive decline. The mechanistic link exists. Whether TRT reverses that risk is a harder question.

The "you could be making yourself less healthy" warning for men who don't need TRT also has support. Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis, can reduce sperm production, and may raise hematocrit, increasing clotting risk, even in otherwise healthy men.

What did they get wrong (or right)?

He got the framing mostly right, and that deserves credit. The risk-benefit calculation for a genuinely hypogonadal man is different from the calculation for someone with testosterone in the normal range who wants more. Most TRT content online ignores this distinction entirely.

What he glosses over is that "clinically deficient" is not a clean binary. Testosterone levels exist on a spectrum, lab reference ranges vary between labs and age groups, and symptoms of low testosterone overlap heavily with symptoms of poor sleep, obesity, and metabolic dysfunction. A single low testosterone reading without proper clinical workup is not a diagnosis of hypogonadism. The American Urological Association guidelines require two morning fasting measurements below 300 ng/dL plus symptoms before initiating treatment. That nuance is missing from his framing.

He also doesn't mention that TRT has known, real risks even in clinically appropriate users: erythrocytosis, testicular atrophy, infertility, and potential sleep apnea worsening. These aren't reasons to avoid TRT when it's indicated, but they're not nothing.

What should you actually know?

If you're considering TRT, the starting point is a proper diagnosis, not a single lab result and a TikTok video. Hypogonadism is a clinical diagnosis that requires confirmed low testosterone levels on at least two separate morning tests, plus symptoms, plus ruling out reversible causes like obesity, poor sleep, and chronic stress.

The cardiovascular safety data has genuinely improved. TRAVERSE was the large, long-term trial the field needed, and its results were reassuring for men with hypogonadism who meet standard prescribing criteria. But TRT is not a cardiovascular prevention strategy. It is a hormone replacement for men whose bodies are not producing adequate testosterone.

The "what's the risk of not treating it" argument he raises is legitimate clinical reasoning, used in endocrinology. Untreated hypogonadism is associated with reduced bone density, increased visceral fat, insulin resistance, and lower quality of life, based on data from Zitzmann (2009, Nature Reviews Urology). These are real consequences. A clinician weighing them against TRT's known side effect profile is doing exactly what they should be doing.

What this video does not replace is that conversation with a qualified clinician who knows your full health picture.